Skip to content

CD16+ Monocytes in Coronary Heart Disease (CHD)

CD16+ Monocytes in Patients With Coronary Heart Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01442948
Acronym
PHAMOS
Enrollment
1000
Registered
2011-09-29
Start date
2007-05-31
Completion date
2010-12-31
Last updated
2011-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Keywords

-CD16+ monocytes

Brief summary

Monocytes may be separated into phenotypically and functionally distinct cell types by the presence or absence of the lipopolysaccharide receptor CD14 and the Fcγ-receptor CD16. The investigators hypothesize that the total numbers of CD16+ monocytes are significantly related to cardiovascular outcome in patients with angiographically proven coronary heart disease.

Interventions

None listed

Sponsors

Martin-Luther-Universität Halle-Wittenberg
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* angiographically proven coronary heart disease * Age \> 18 years

Exclusion criteria

* life expectancy \< 12 months * inability to participate in the trial (to give written informed consent)

Design outcomes

Primary

MeasureTime frameDescription
Absolute numbers of CD16+ monocytes stratified by tertiles related to the incidence of the combined endpoint12 monthsIncidence of the combined endpoint (non-fatal myocardial infarction, cardiovascular death, stroke) during a follow-up of 12 months

Secondary

MeasureTime frameDescription
Absolute numbers of CD16+ monocytes stratified by tertiles related to the incidence of each part of the combined endpoint + total death12 months* non-fatal myocardial infarction * cardiovascular death * stroke * total death
Subgroup analysis for absolute numbers of CD16+ monocytes stratified by tertiles in relation to the combined endpoint12 monthsSubgroups of patients: Patients with stable Angina Patients with acute coronary syndrome

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026